| MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study R Pötter, K Tanderup, MP Schmid, I Jürgenliemk-Schulz, C Haie-Meder, ... The Lancet Oncology 22 (4), 538-547, 2021 | 402 | 2021 |
| Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses H Zhang, TU Ahearn, J Lecarpentier, D Barnes, J Beesley, G Qi, X Jiang, ... Nature genetics 52 (6), 572-581, 2020 | 354 | 2020 |
| SIOPE–Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy T Ajithkumar, G Horan, L Padovani, N Thorp, B Timmermann, C Alapetite, ... Radiotherapy and Oncology 128 (2), 192-197, 2018 | 92 | 2018 |
| Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomics D De Ruysscher, H Sharifi, G Defraene, SL Kerns, M Christiaens, ... Acta oncologica 52 (7), 1405-1410, 2013 | 75 | 2013 |
| Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma E Van Der Steen-Banasik, M Christiaens, E Shash, C Coens, A Casado, ... European Journal of Cancer 65, 172-181, 2016 | 52 | 2016 |
| Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047 … D Lorusso, Y Xiang, K Hasegawa, G Scambia, M Leiva, P Ramos-Elias, ... The Lancet 403 (10434), 1341-1350, 2024 | 47 | 2024 |
| ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. D Lorusso, N Colombo, RL Coleman, LM Randall, LR Duska, Y Xiang, ... Journal of Clinical Oncology 38 (15_suppl), TPS6096-TPS6096, 2020 | 34 | 2020 |
| Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: results of the benchmark case … M Christiaens, S Collette, J Overgaard, V Gregoire, J Kazmierska, ... Radiotherapy and Oncology 123 (3), 424-430, 2017 | 21 | 2017 |
| A comparison of a brachytherapy and an external beam radiotherapy boost in breast-conserving therapy for breast cancer: local and any recurrences I Kindts, K Verhoeven, A Laenen, M Christiaens, H Janssen, ... Strahlentherapie und Onkologie 195 (4), 310-317, 2019 | 18 | 2019 |
| Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes F Deman, K Punie, A Laenen, P Neven, E Oldenburger, A Smeets, ... Breast Cancer Research and Treatment 184, 985-998, 2020 | 17 | 2020 |
| Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC) ER Del Campo, O Matzinger, K Haustermans, D Peiffert, R Glynne-Jones, ... European Journal of Cancer 121, 130-143, 2019 | 17 | 2019 |
| European Organisation for Research and Treatment of Cancer, Gynaecological Cancer Group (EORTC-GCG): Systemic review: Radiation therapy alone in medical non-operable … E Van der Steen-Banasik, M Christiaens, E Shash, C Coens, A Casado, ... Eur J Cancer 65, 172-181, 2016 | 14 | 2016 |
| Comparison of brachytherapy and external beam radiotherapy boost in breast-conserving therapy: patient-reported outcome measures and aesthetic outcome I Kindts, A Laenen, M Christiaens, H Janssen, E Van Limbergen, ... Strahlentherapie und Onkologie 195 (1), 21-31, 2019 | 13 | 2019 |
| Beam output audit results within the EORTC radiation oncology group network CW Hurkmans, M Christiaens, S Collette, DC Weber Radiation oncology 11, 1-6, 2016 | 13 | 2016 |
| EMBRACE Study; GEMO Study Collaborators. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses H Zhang, TU Ahearn, J Lecarpentier, D Barnes, J Beesley, G Qi, X Jiang, ... Nat Genet 52 (6), 572-581, 2020 | 11 | 2020 |
| Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria J Haesen, R Salihi, T Van Gorp, E Van Nieuwenhuysen, SN Han, ... Gynecologic oncology 162 (3), 539-545, 2021 | 9 | 2021 |
| Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk J Liu, WJC Prager-van der Smissen, JM Collee, MK Bolla, Q Wang, ... Scientific reports 10 (1), 9688, 2020 | 6 | 2020 |
| 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab+ chemoradiotherapy for high-risk locally advanced cervical cancer D Lorusso, Y Xiang, N Colombo, RL Coleman, LM Randall, L Duska, ... International Journal of Gynecologic Cancer 31 (Suppl 3), 2021 | 4 | 2021 |
| Retrospective analysis of the clinical presentation, treatment and outcome of angiosarcoma in a sarcoma referral center P Schöffski, I Timmermans, H Wildiers, H Dumez, D Hompes, ... Oncology Research and Treatment 44 (6), 322-332, 2021 | 3 | 2021 |
| 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer D Lorusso, Y Xiang, N Colombo, R Coleman, L Randall, L Duska, ... Annals of Oncology 31, S1341-S1342, 2020 | 3 | 2020 |
